Q: What type of protected health information (PHI) can be used for marketing? Are authorizations always necessary when using PHI for marketing purposes? If not, what are some situations when patient authorization would not be required?
Q: During the novel coronavirus (COVID-19) pandemic, it has become abundantly clear that the burden from this disease has not been shared equally. Minorities have been disproportionately affected, and many of the problems are due to structural inequalities that existed long before the pandemic began. How can case managers address some of these underlying problems in hopes of improving health equality?
Q: The 2021 Inpatient Prospective Payment System (IPPS) final rule requires providers to transmit all records to Quality Improvement Organizations (QIO) electronically. How can organizations make sure that they are in compliance if they’re not already?
Q: If we end a contract with a business associate (BA), does the BA need to provide us with assurance that all protected health information (PHI) has been destroyed? Is this something that should be written into the initial contract? What are the steps to take if the BA does not respond to requests to confirm deletion of PHI?
